| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg | |||
| Other Sizes |
| Targets |
Suxibuzone is a prodrug of phenylbutazone, and its anti-inflammatory effects are mediated through the inhibition of cyclooxygenase (COX) enzymes. By inhibiting COX-1 and COX-2, it reduces the production of prostaglandins, which are mediators of inflammation and pain.
|
|---|---|
| ln Vitro |
Suxibuzone is a non-steroidal anti-inflammatory drug (NSAID). It is a prodrug of phenylbutazone. Its anti-inflammatory effects are mediated through the inhibition of COX enzymes.
|
| ln Vivo |
Suxibuzone is used in vivo as an NSAID for the treatment of pain and inflammation. It is a prodrug of phenylbutazone. It is used in medical, environmental, and industrial research.
|
| Enzyme Assay |
Suxibuzone is an NSAID, and its in vitro activity is assessed in enzyme assays. In a typical assay, the inhibition of COX-1 and COX-2 activity is measured. The compound is incubated with the enzyme and a substrate, and the production of prostaglandins is measured.
|
| Cell Assay |
Suxibuzone is dissolved in DMSO and applied to cultured cells at concentrations ranging from 1 µM to 100 µM. The effect on prostaglandin production and inflammatory markers is assessed.
|
| ADME/Pharmacokinetics |
Suxibuzone has a molecular weight of 438.47 g/mol and a molecular formula of C24H26N2O6. It is a non-steroidal anti-inflammatory drug. The compound is typically stored as a powder at -20°C for long-term stability. Suxibuzone is also known as 琥布宗.
|
| Toxicity/Toxicokinetics |
Oral LD50 in mice is 5.683 micromol/kg. Suxibuzone has a manageable toxicity profile consistent with other NSAIDs. Common side effects include gastrointestinal disturbances, such as nausea, vomiting, and abdominal pain. The risk of gastrointestinal bleeding and ulceration is associated with NSAID use. Renal toxicity and cardiovascular risks are also associated with NSAIDs.
|
| Additional Infomation |
Susibutrone is a pyrazolidine compound, a derivative of phenazorone with a 3-carboxypropionylmethyl substituted at the 4-position. Susibutrone is a prodrug of phenazorone and is commonly used for anti-inflammatory treatment in horses. It has various pharmacological effects, including as a prodrug, nonsteroidal anti-inflammatory drug (NSAID), antirheumatic drug, non-narcotic analgesic, and peripheral nervous system drug. It belongs to the pyrazolidine class of compounds and is a monocarboxylic acid and hemisuccinate.
Suxibuzone is a non-steroidal anti-inflammatory drug (NSAID) used to treat pain and inflammation. It is a prodrug of the non-steroidal anti-inflammatory drug phenylbutazone. Suxibuzone is a 4-butyl-4-(hydroxymethyl)-1,2-diphenyl-3,5-pyrazolidinedione hydrogen succinate. It was first synthesized in the 1960s. |
| Molecular Formula |
C24H26N2O6
|
|---|---|
| Molecular Weight |
438.48
|
| Exact Mass |
438.179
|
| CAS # |
27470-51-5
|
| PubChem CID |
5362
|
| Appearance |
White to off-white solid powder
|
| Density |
1.265g/cm3
|
| Boiling Point |
590.1ºC at 760 mmHg
|
| Melting Point |
126-127°
|
| Flash Point |
310.7ºC
|
| Vapour Pressure |
9.05E-15mmHg at 25°C
|
| Index of Refraction |
1.579
|
| LogP |
3.696
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
11
|
| Heavy Atom Count |
32
|
| Complexity |
661
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O=C(OCC1(CCCC)C(N(C2=CC=CC=C2)N(C3=CC=CC=C3)C1=O)=O)CCC(O)=O
|
| InChi Key |
ONWXNHPOAGOMTG-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C24H26N2O6/c1-2-3-16-24(17-32-21(29)15-14-20(27)28)22(30)25(18-10-6-4-7-11-18)26(23(24)31)19-12-8-5-9-13-19/h4-13H,2-3,14-17H2,1H3,(H,27,28)
|
| Chemical Name |
4-[(4-butyl-3,5-dioxo-1,2-diphenylpyrazolidin-4-yl)methoxy]-4-oxobutanoic acid
|
| Synonyms |
AE 17; AE17; AE-17
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ≥ 100 mg/mL (~228.07 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (5.70 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (5.70 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (5.70 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.2806 mL | 11.4030 mL | 22.8061 mL | |
| 5 mM | 0.4561 mL | 2.2806 mL | 4.5612 mL | |
| 10 mM | 0.2281 mL | 1.1403 mL | 2.2806 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
